QuantaMatrix, Inc.

QuantaMatrix, Inc.

KKRX:317690
1,640.00
KRW
-41.00
(-2.44%)
-899.03EPS
51.14BMarket Cap
QuantaMatrix, Inc.
KRX:317690
(Korea Stock Exchange)

Recent

price

1,640.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
46.96
21.47
129.79
131.26
36.54
78.01
188.76
151.05
199.38
158.41
Revenue per Share
-12,538
-3,920
-10,207
-1,139
-1,204
-1,167
-1,305
-1,220
-1,052
-899.03
Basic EPS, GAAP
-7,012.51
-2,324.72
-2,493.48
-1,116.84
-1,244.53
-1,093
-1,361.67
-814.36
-851.33
-854.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-11,959.19
-2,498.18
1,818.25
3,916.69
3,543.87
2,419.96
1,095.69
394.78
1,986.86
1,594.27
Book Value per Share
-12,163.42
-2,520.21
1,796.96
3,899.68
3,478.38
2,321.01
983.61
291.79
1,935.53
1,544.37
Tangible Book Value per Share
1
4
6
13
15
16
17
17
18
20
Basic Weighted Avg Shares
47
85
811
1,689
550
1,286
3,118
2,497
3,688
3,145
Sales/Revenue/Turnover
-18,005.02
-13,080.64
-1,798.72
-878.93
-3,350.94
-1,558.78
-720.58
-647.19
-421.98
-527.06
Operating Margin (%)
577
888
1,437
1,799
2,119
2,377
2,394
2,396
2,181
2,175
Depreciation Expense
-12,423
-15,512
-63,811
-14,659
-18,116
-19,237
-21,556
-20,169
-19,460
-17,849
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-26,699.35
-18,261.83
-7,864.48
-867.72
-3,295.13
-1,495.97
-691.35
-807.67
-527.63
-567.54
Profit Margin (%)
-12,867
-10,861
25,938
53,500
52,526
31,735
10,958
15,642
36,884
27,841
Working Capital
4,418
- -
1,384
1,258
1,319
857
523
15,930
438
706
LT Debt
-26,671
-40,228
29,279
57,399
58,392
39,879
18,120
6,531
40,005
32,101
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-33.82
-31.29
-39.15
-74.33
-163.64
-83.64
-96.89
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9,143
5,411
5,301
LT Borrowings
- -
- -
- -
LT Finance Leases
438
877
706
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
96,447
73,191
51,143

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
48,150
42,062
37,413
Cash, Cash Equivalents & STI
41,541
38,313
30,244
Accounts Receivable, Net
1,852
- -
- -
Inventories
3,326
3,265
2,668
Total Current Liabilities
11,266
10,197
9,571
Payables & Accruals
- -
- -
- -
ST Debt
9,143
5,411
5,301
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
72.82%
512.58%
Free Cash Flow
- -
5.63%
16.98%
Net Income, GAAP
- -
6.37%
-3.51%
Sales/Revenue/Turnover
- -
47.34%
47.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
788
607
647
455
2,497
2025
1,018
898
980
794
3,688
2026
726
646
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-261
-158
-240
-560.43
-1,220
2025
-242
-328
-207.33
-270.51
-1,052
2026
-231.65
-189
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
QuantaMatrix, Inc. (KRX: 317690) is a South Korea-based in vitro diagnostics company that develops and commercializes advanced clinical microbiology, molecular diagnostics, and immunoassay platforms designed to combat antimicrobial resistance and accelerate critical care diagnostics. Founded in 2010 as a spin-off from Seoul National University and headquartered in Seoul, South Korea, the company operates internationally with regional European operations based in Villejuif, France, and commercial distribution networks spanning Europe, the Middle East, and Asia. The company categorizes its primary product portfolio across rapid antimicrobial susceptibility testing, infectious disease screening, and automated multi-marker immunoassays: dRAST (direct & Rapid Antimicrobial Susceptibility Testing), an automated clinical platform that provides phenotypic antimicrobial susceptibility test results directly from positive blood culture samples in as little as four to six hours, utilizing microfluidic agarose channels, time-lapse microscopic imaging, and artificial intelligence-driven diagnostic algorithms to guide targeted antibiotic prescription for sepsis; QDST (QuantaMatrix Drug Susceptibility Testing), a rapid phenotypic susceptibility testing system engineered to determine tuberculosis drug resistance in approximately seven days compared to conventional multi-week workflows; QPLEX Alz plus assay, a multi-biomarker in vitro diagnostic kit engineered for early-stage Alzheimer's disease risk assessment via standard blood draws; QMIA (QuantaMatrix Immunoassay Analyzer), an automated multiplex immunoassay instrument utilizing encoded Microdisk technology; and Quanti9 and QuantiGal, prognostic biomarker assay kits utilized for cardiovascular disease research and stratification. In recent corporate developments, QuantaMatrix has advanced its technological pipeline, regulatory reach, and global commercialization footprint. In September 2025, the company was awarded 2.85 million USD in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to develop an ultra-rapid diagnostic platform tailored for neonatal sepsis using low-volume blood samples. In 2024, the company unveiled its next-generation uRAST (Ultra-Rapid Antimicrobial Susceptibility Testing) technology in Nature, demonstrating direct phenotypic susceptibility testing from whole blood within 13 hours without preliminary blood culture incubation. To accelerate international market penetration, QuantaMatrix secured European In Vitro Diagnostic Medical Devices Regulation (IVDR) CE certification for its dRAST platform, secured diagnostic tenders including the Great Orchestra of Christmas Charity (WOSP) contract in Poland, established an exclusive distribution partnership with Neo-Science to expand commercial availability across the United Arab Emirates and the Middle East, and advanced pre-submission regulatory discussions under the 510(k) pathway with the U.S. Food and Drug Administration (FDA) to support clinical entry into the North American market.